linjc16/ctgov huggingface dataset:
Prognostic Model of Hypertension

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to establish a registration and monitoring system for hypertension in Xinjiang from 2020 to 2030 to obtain real information about patient basic information, patient characteristics, diagnostic test patterns, treatment options, and hospitalization outcomes (including mortality). Treatment complications, hospitalization costs, and end-of-life events (death, major adverse cardiac events, mild adverse cardiovascular events) in patients with hypertension in Xinjiang; and scientific prevention strategies aimed at effectively preventing the onset of hypertension; Guidelines in clinical practice recommend, analyze and develop effective treatment strategies to optimize management and outcomes for patients with hypertension; and create cost-effective assessment systems.

Detailed Description
-----------------
The aim of the study is to establish a platform for monitoring, clinical research and translational medicine in Xinjiang, which aims to provide a basis for future quality improvement and research, and to promote efforts to improve the prognosis of patients with hypertension, and to translate research into improved care for patients, thereby reducing Morbidity and mortality associated with hypertension.

Official Title
-----------------
Prognostic Model of Hypertension

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Other: Standard therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A patient diagnosed with primary hypertension who was admitted to the First Affiliated Hospital of Xinjiang Medical University Exclusion Criteria: Patients with secondary hypertension, patients with liver and kidney dysfunction, patients with mental disorders, and patients who are unwilling to participate in this trial
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 2<br> | Other: Standard therapy<br>* Individualized blood pressure reduction program<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Death (all-cause mortality, mortality from hypertension complications) |  | 10 years of follow-up deaths occurred during this period | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major adverse cardiovascular events |  | 10 years of follow-up deaths occurred during this period |
Wound Catheter Vs LA Bolus in Renal Transplant: RCT

Study Overview
=================
Brief Summary
-----------------
Pain control is an important part of patients' care after a kidney transplant. Currently patients receive a one off injection of Local Anaesthetic (LA) in the wound at the end of the operation followed by Intravenous morphine through a Patient Controlled Analgesia System (PCAS), a button pressed to provide a calculated dose with lock out times for safety. Through this study the aim to test the efficiency of Continuous Local Anaesthetic Infiltration via Wound Catheter (LAWC) which is a method to deliver Local Anaesthetic over a longer period of time after the operation. LAWC are currently in use in a variety of surgical specialities including Liver surgery. Patients participating in this study will be allocated randomly to one of 2 groups; one will receive LA at the end of the operation as per current practice and one will receive LAWC. It then compare outcomes such as the the dose of morphine required in the PCAS, quality of pain control and improvement in recovery.

Official Title
-----------------
Wound Catheter Vs LA Bolus in Renal Transplant: RCT

Conditions
-----------------
Wound

Intervention / Treatment
-----------------
* Device: Local Anaesthetic Wound Catheter Insertion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary kidney transplantation Single kidney transplantation Signed informed Consent Exclusion Criteria: Midline laparotomy Dual kidney transplantation Kidney re-transplantation Multi-organ transplantation Patients on Long term opiates Patients with psychiatric illness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Local Anaesthetic Wound Catheter Insertion|Use of the Local Anaesthetic Wound Catheter Insertion during kidney transplant|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total Dose of IV Morphine in the first 24 hours post op | Measurment of the dose delivered in 24 hours | 24 hours |
Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to assess serious adverse events associated with hospitalizations in the non-acute phase after vaccination with the mRNA-1273 vaccine in persons with underlying diseases who are considered to have a high risk of severe exacerbation of COVID-19.

Detailed Description
-----------------
Data collected from the JMDC Claims database from May 2020 to October 2022.

Official Title
-----------------
Cohort Survey on Non-Acute Safety in Persons With Underlying Diseases Who Are Considered to Be at High Risk of Severe COVID-19 by Using Vaccination Information

Conditions
-----------------
SARS-CoV-2

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants registered to receive the mRNA-1273 vaccine in the Pep Up vaccination history Database Participants who have a history of vaccination with the mRNA-1273 vaccine in the Pep-Up vaccination history Database and the observation start date is at least 6 months prior to vaccination with the mRNA-1273 vaccine and have underlying diseases. Exclusion Criteria: Underlying diseases that were determined undetectable by the pre-screening of JMDC Participants who did not consent to the questionnaire.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cohort 1<br>Participants received 2 doses of mRNA-1273 vaccine approximately 4 weeks apart. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With Serious Events Associated With all-Cause Hospitalizations |  | Up to 1 year post vaccination | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Moderna, COVID-19, COVID-19 Vaccine, mRNA-1273, mRNA-1273 vaccine, SARS-CoV-2, SARS-CoV-2 Vaccine, Coronavirus, Virus Diseases, Messenger RNA
FFP Usage in Pediatric CV Surgery

Study Overview
=================
Brief Summary
-----------------
When small children undergo heart surgery with the heart-lung machine, in the past, blood products to help the blood clot such as Fresh Frozen Plasma (FFP) was routinely used in children under 10kg. With blood clot monitoring technology, we feel that it might not be necessary to expose all children to FFP. We want to determine if those children who did not receive FFP bleed more or require more blood products as compared to those who did receive FFP while on the heart lung machine.

Detailed Description
-----------------
This will be a single center, retrospective study. Our cohort will include pediatric patients between 4 and 8 kilograms undergoing congenital cardiac surgery with cardiopulmonary bypass between January 2019 and January 2023. Patients will be divided into two groups: FFP given at onset of CPB and no FFP given intraoperatively. Patients requiring FFP for heparin resistance and anti-thrombin III deficiency will be excluded. Patient clinical, surgical, and bypass characteristics, transfusion, and bleeding outcomes will be collected using REDCAP and via chart review using Connect Care.

Official Title
-----------------
Outcomes of Fresh Frozen Plasma Usage During Cardiopulmonary Bypass in Congenital Cardiac Surgery.

Conditions
-----------------
Coagulopathy, Congenital Heart Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pediatric patients between 4 and 8 kilograms undergoing congenital cardiac surgery with cardiopulmonary bypass Exclusion Criteria: Patients requiring FFP for heparin resistance and anti-thrombin III deficiency will be excluded

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| FFP<br>Patients undergoing CPB receiving FFP | |
| no FFP<br>Patients undergoing CPB not receiving FFP | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Transfusion | Units of blood products transfused | 24 hours | 
| Bleeding | Chest tube output | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of ventilation | Time to extubation | 5 days | 
| Length of stay | Time to ICU ready for discharge | 5 days |
Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

Study Overview
=================
Brief Summary
-----------------
This is a single-arm, open-label study to assess the reduction of low-density lipoprotein cholesterol (LDL-C) by SHR-1918 in patients with homozygous familial hypercholesterolemia (HoFH).

Official Title
-----------------
A Single-Arm, Open-Label, Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

Conditions
-----------------
Homozygous Familial Hypercholesterolemia

Intervention / Treatment
-----------------
* Drug: SHR-1918


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of functional HoFH by either genetic or clinical criteria as defined in the protocol LDL-C ≥2.6mmol/L at the screening visit Body weight ≥40 kg Receiving stable lipid-lowering therapy for at least 28 days before enrollment. Exclusion Criteria: Previously diagnosed type 1 diabetes or poorly controlled type 2 diabetes at screening (HbA1c > 8.5%) eGFR <30ml/min/1.73m2 at the screening visit CK >5times ULN at the screening visit

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: SHR-1918<br> | Drug: SHR-1918<br>* Three administration<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent change in calculated LDL-C from baseline to week 12 |  | from baseline to week 12 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in calculated LDL-C from baseline to week 12 |  | from baseline to week 12 |
Analysis of Intraoperative Bleeding Characteristics in Laparoscopic Pancreaticoduodenectomy

Study Overview
=================
Brief Summary
-----------------
In this study, we analyze the common bleeding characteristics in laparoscopic pancreaticoduodenectomy by reviewing and annotating bleeding information from previous surgical videos as well as surgical operation OSATS technique scores. From there, we reflect on the correlation between surgical operating technique and intraoperative bleeding, as well as on the correlation between intraoperative bleeding and short-term postoperative outcomes.

Official Title
-----------------
Analysis of Intraoperative Bleeding Characteristics in Laparoscopic Pancreaticoduodenectomy

Conditions
-----------------
Laparoscopic Pancreaticoduodenectomy

Intervention / Treatment
-----------------
* Procedure: laparoscopic pancreaticoduodenectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: the surgical video is complete including the resection and reconstruction phases Exclusion Criteria: the surgical video is not complete the cases combined with resection and reconstruction of mesentericoportal vein
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| LPD group<br>Cases who had underwent laparoscopic pancreaticoduodenectomy | Procedure: laparoscopic pancreaticoduodenectomy<br>* laparoscopic pancreaticoduodenectomy was performed for periampullary benign and malignant diseases. Besides, the surgical video was recorded.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| intraoperative bleeding characteristics | Bleeding characteristics include cause of bleeding, site of bleeding, size of bleeding, method of hemostasis, duration of hemostasis, and outcome of hemostasis. These would be obtained by reviewing and labeling laparoscopic pancreaticoduodenectomy surgical videos. | intraoperatively | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OSATS scores | Scoring laparoscopic pancreaticoduodenectomy operations using the OSATS Surgical Operative Technique Rating Scale | intraoperatively | 
| textbook outcome | The textbook outcome was defined as the absence of all six individual outcomes: clinically relevant postoperative pancreatic fistula, post-pancreatectomy hemorrhage, bile leak, severe complications (Clavien-Dindo≥3), readmission, and mortality within 30 days postoperatively | 3 months postoperatively | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
laparoscopic pancreaticoduodenectomy, intraoperative bleeding, OSATS scores, short-time outcomes
Study of a Series of Patients Treated for Retrograde Cricopharyngeal Muscle Dysfunction Syndrome

Study Overview
=================
Brief Summary
-----------------
R-CPD syndrome (Retrograde Cricopharyngeal Dysfunction syndrome) is an inability to burp. It is a syndrome whose diagnosis is clinical, and for which there is effective treatment. Recently treated in the United States (first publication in 2019), this syndrome affects many patients in France and is currently unknown. This study concerns a series of patients treated at the University Hospitals of Strasbourg for a syndrome of retrograde dysfunction of the cricopharyngeus muscle having been treated by injection of botulinum toxin into the cricopharyngeus muscle.

Official Title
-----------------
Study of a Series of Patients Treated for Retrograde Cricopharyngeal Muscle Dysfunction Syndrome

Conditions
-----------------
Deglutition Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major subject (≥18 years old) Subject treated by injection of botulinum toxin into the cricopharyngeal muscle after having had a diagnosis of R-CPD in consultation between January 1, 2022 and December 31, 2022 Subject not opposing the reuse of their data for the purposes of this research. Exclusion Criteria: Subject having expressed opposition to participating in the study, Subject under judicial protection Subject under guardianship or curatorship

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retrospective description of the characteristics of a series of patients treated for dysphagia syndrome | Retrospective study of medical files of patients treated in HUS between January 1, 2022 and December 31, 2022 | Through study completion, an average of 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Deglutition Disorders, Dysphagia, cricopharyngeus muscle, Circular sphincter, Esophagus, Botulinum toxin
Evaluation of the POSOS Device for Iatrogenesis Detection in Clinical History? A Vignettes Study

Study Overview
=================
Brief Summary
-----------------
This study is a multicenter evaluation of diagnostic performance using simulated clinical vignettes. It aims to test the effectiveness of the POSOS app in detecting drug-induced iatrogenesis in urgent medical situations, an issue of public health importance. Participating physicians, who are randomly assigned to either use or not use POSOS, are categorized based on their years of experience. Vignettes, including a mixture of complex, simple, and non-iatrogenesis cases, are assigned to these doctors. During the simulation, physicians respond to their respective vignettes on the YgheniVi platform, with responses recorded at two intervals (5 min and 15 min). The supervising physicians subsequently fill out an e-CRF, providing further data on the time spent, the number of medical research applications used, and the overall user experience of POSOS. A doctor/pharmacist pair then corrects the answers to the vignettes.

Official Title
-----------------
Evaluation of the POSOS Device for Iatrogenesis Detection in Clinical History? A Vignettes Study

Conditions
-----------------
Iatrogenesis, Clinical Vignettes, Diagnostic Performance Study, Medical Information Search, Artificial Intelligence

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Not applicable as the study population is made up of clinical vignettes, there is no inclusion of patients. The physicians included are emergency physicians, selected by convenience so as to have as many physicians (seniority of practice 3 years after thesis) as (seniority of practice less). Exclusion Criteria: Not applicable. Simulations with technical faults will be excluded: (absence of the test doctor, internet access not working, PC malfunction, serious disruptions during the simulation).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| seniority ≥3 years + POSOS<br> | |
| seniority ≥3 years without POSOS<br> | |
| seniority <3 years with POSOS<br> | |
| seniority <3 years without POSOS<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the proportion of overall correct responses in each groups |  | 5 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Iatrogenesis, Clinical vignettes, Diagnostic performance study, Medical Information Search, Artificial Intelligence
Percutaneous Imaging-guided Cryoblation of the Anterior Abdominal Wall Endometriosis Scars

Study Overview
=================
Brief Summary
-----------------
Endometriosis is a common condition affecting 10% of women. It is characterized by the presence of ectopic endometrial cells. This pathology most frequently develops in the ovaries, utero-sacral ligaments and pelvic peritoneum, but also in the recto-sigmoid. Rarely, these lesions are found outside the pelvis, and even more exceptionally in the abdominal wall (in 0.03 to 1% of cases). Cryotherapy has already been used for many years to treat soft tissue tumors (kidney and prostate tumors). It has also been successfully used by interventional radiologists to treat parietal desmoid tumors. After discussions with radiologists, given the similarity of location and extension of wall endometriosis lesions with desmoid tumours, the successes observed, and the scarcity of studies in the literature, it seemed appropriate to the investigators to study this new therapy. The aim of this study was to investigate the efficacy of cryotherapy on parietal endometriosis lesions.

Official Title
-----------------
Percutaneous Imaging-guided Cryoblation of the Anterior Abdominal Wall Endometriosis Scars

Conditions
-----------------
Endometriosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult woman (≥18 years old) Having benefited from cryotherapy of an abdominal wall endometriosis nodule between January 6, 2020 and January 2, 2023. Subject not objecting to the reuse of their data for the purposes of this research Exclusion Criteria: Subject having expressed its opposition to the reuse of its data for scientific research purposes.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of cryotherapy on parietal endometriosis lesions was assessed using the a visual analogue scale (VAS) ranging from 0 to 10. |  | Before and 6 months after the cryotherapy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Endometriosis, Endometrial cells, Radiofrequency, Anterior abdominal, Cryotherapy